Adcetris

Role

Indications

Reactions

Primary

Hodgkin's Disease	41.9%
Product Used For Unknown Indication	22.2%
Anaplastic Large Cell Lymphoma T- And Null-cell Types	7.9%
Hodgkin's Disease Recurrent	5.4%
Lymphoma	3.4%
Anaplastic Large-cell Lymphoma	3.0%
Hodgkin's Disease Nodular Sclerosis Stage Unspecified	2.0%
Hodgkin's Lymphoma	2.0%
Mycosis Fungoides	2.0%
Adult T-cell Lymphoma/leukaemia	1.5%
Non-hodgkin's Lymphoma	1.5%
Non-hodgkin's Lymphoma Refractory	1.5%
Anaplastic Large Cell Lymphoma T- And Null-cell Types Recurrent	1.0%
Anaplastic Large Cell Lymphoma T- And Null-cell Types Stage Iv	1.0%
Hodgkin's Disease Refractory	1.0%
Non-hodgkin's Lymphoma Recurrent	1.0%
Anaplastic Large-cell Lymphoma, Primary Systemic Type	0.5%
B-cell Small Lymphocytic Lymphoma	0.5%
Chronic Lymphocytic Leukaemia Refractory	0.5%
Diffuse Large B-cell Lymphoma	0.5%

Hodgkin's Disease	10.5%
Sepsis	9.2%
Neuropathy Peripheral	7.9%
Pneumonia	7.9%
Death	6.6%
Pain	5.3%
Pancreatitis	5.3%
Rectal Haemorrhage	5.3%
Blood Creatinine Increased	3.9%
Lung Disorder	3.9%
Pneumonitis	3.9%
Pulmonary Toxicity	3.9%
Reading Disorder	3.9%
Respiratory Failure	3.9%
Thrombocytopenia	3.9%
Vomiting	3.9%
Anaphylactic Reaction	2.6%
Arrhythmia	2.6%
Aspartate Aminotransferase Increased	2.6%
Cardiogenic Shock	2.6%

Secondary

Product Used For Unknown Indication	36.8%
Hiv Infection	15.8%
Antiemetic Supportive Care	7.9%
Hodgkin's Disease	7.9%
Prophylaxis	7.9%
Asymptomatic Hiv Infection	5.3%
Blood Glucose Increased	5.3%
Anaplastic Large Cell Lymphoma T- And Null-cell Types	2.6%
Antibiotic Prophylaxis	2.6%
Diabetic Neuropathy	2.6%
Gastrointestinal Disorder	2.6%
Non-hodgkin's Lymphoma	2.6%